Reducing Amyloid Beta Levels in Alzheimer’s

brain lifesaver

The brains of Alzheimer patients produce a toxic substance called amyloid beta which forms plaque deposits.

The sufferers brain’s natural defender cells are unable to eliminate the amyloid substance.
Researchers from Université Laval, CHU de Québec, and pharmaceutical firm GlaxoSmithKline (GSK) however have found a molecule that stimulates the activity in the brain’s immune cells and was able to eliminate 80% of plaques in mice over a 12 week period.

Future uses for this molecule (monophosphoryl lipid A or MPA) if successful with humans include slowing the progression of Alzheimer’s and as a vaccine for at risk groups.


Major step toward an Alzheimer’s vaccine